
MATERIAL SAFETY DATA SHEET

Section 1: IDENTIFICATION of CHEMICAL PRODUCT and COMPANY

Product Name:	VetACE 2.5 mg Tablets for Dogs and Cats VetACE 5 mg Tablets for Dogs and Cats VetACE 20 mg Tablets for Dogs
Product Code:	504045 (2.5 mg); 504060 (5 mg); 504055 (20 mg)
Recommended Use:	For the treatment of heart failure in dogs due to mitral regurgitation (endocardiosis) and dilated cardiomyopathy, and both chronic renal insufficiency and hypertrophic cardiomyopathy in cats.
Company Identification:	Jurox Pty Limited
Address:	85 Gardiner Road Rutherford NSW 2320 Australia
Customer Centre:	1800 023 312
National Poisons Information Centre:	131 126 (Australia-wide)
Emergency Telephone Number:	1800 023 312

Section 2: HAZARDS IDENTIFICATION

Hazard Classifications:	Not considered a Hazardous Substance according to the criteria of NOHSC Australia. Not considered a Dangerous Good according to the criteria of the Australian Dangerous Goods (ADG) Code.
Poisons Schedule:	S4
Risk phrases:	None
Safety phrases:	None

Section 3: COMPOSITION / INFORMATION on INGREDIENTS**VetACE 2.5 mg and 5 mg Tablets for Dogs and Cats**

INGREDIENT	CAS No.	CONTENT
Benazepril Hydrochloride	86541-74-4	2.6%
Other non-hazardous ingredients		97.4%

VetACE 20 mg Tablets for Dogs

INGREDIENT	CAS No.	CONTENT
Benazepril Hydrochloride	86541-74-4	10.4%
Other non-hazardous ingredients		89.6%

Section 4: FIRST AID MEASURES

- First Aid Measures:** Consult the National Poisons Centre on 131126 or a doctor immediately in every case of suspected chemical poisoning. Never give fluids or induce vomiting if a patient is unconscious or convulsing regardless of cause of injury. If medical advice/attention is needed, have product container or label at hand.
- Inhalation:** Remove patient to fresh air. Lay patient down and keep warm and rested. If breathing is shallow or has stopped, ensure airway is clear and apply resuscitation. If breathing is difficult, give oxygen. Seek medical assistance immediately.
- Ingestion:** If swallowed, DO NOT induce vomiting. Rinse mouth. Keep subject warm and at rest. For advice, contact the National Poisons Centre on 131126. Seek medical assistance immediately.
- Skin:** If skin contact occurs, wash affected area thoroughly with plenty of soap and water for at least 15 minutes. If skin irritation or rash occurs, get medical advice/attention. Remove and wash / dispose of contaminated clothing promptly. Unlikely to arise from unbroken tablets.
- Eye:** If eye contact occurs, rinse cautiously with water for at least 20 minutes. Continue rinsing. If eye irritation persists, get medical advice/attention.
- Advice to Doctor:** The side effects of therapeutic use of benazepril include headache, cough, hypotension, dizziness, fatigue, nausea, angioedema (face, tongue and extremities) and dermatitis. The most significant sign of poisoning is likely to be marked hypotension. The active metabolite, benazeprilat, cannot be eliminated to a significant degree by dialysis.

Section 5: FIRE FIGHTING MEASURES

- Flash Point:** Not flammable
- Hazardous Combustion Products:** If involved in a fire, the active ingredient benazepril may evolve toxic fumes.
- Extinguishing Media:** There is no restriction on the type of fire extinguisher which may be used. Use extinguishing media appropriate for surrounding area.
- Protective Equipment:** Gas-tight chemical resistant suit, protective gloves and breathing apparatus
- HAZCHEM Code:** Not allocated.

Section 6: ACCIDENTAL RELEASE MEASURES

- Spills and Disposal:** Wear appropriate protective clothing. Exclude non-essential people from the area. Contain spill and sweep up / absorb with inert material such as soil, sand or absorbent granules and place in a sealable waste container. Avoid raising dust. Ventilate area and wash spill site after pick-up complete. Dispose of waste safely in an approved landfill.
- Protective Clothing:** For appropriate personal protective equipment see section 8.
- Environmental Precautions:** Prevent from entering drains, waterways or sewers. If spill does enter waterways contact local authority.

Section 7: HANDLING AND STORAGE

- Handling:** This is a Schedule 4 (Prescription Animal Remedy) product, available only to or through a veterinarian. Do not handle this product if you are sensitised or if you have been advised not to work with such preparations. Handle this product with care to avoid exposure, taking all recommended precautions. Avoid contact with skin and eyes. Wash hands after use. Use other personal protective equipment as required.
- Storage:** Store below 30°C. Protect from heat and moisture. Unused half tablets should be returned to the open blister pack, inserted into the cardboard box and stored safely.
- Other Information:** Always read the label before use.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

- Exposure Limits:** The occupational toxicity risk is low from the tablet form. The occupational exposure standard for benazepril hydrochloride is 0.02 mg/m³ (USA value). Avoid breathing vapours. Do not handle until all safety precautions have been read and understood.
- Protective Equipment:** Unnecessary for the tablet dosage form. Although not considered hazardous when handled under normal conditions with good house keeping, when handling the bulk product it is advisable to wear protective gloves, clothing and eyewear.
- Engineering Controls:** Not applicable for normal use. Handle bulk product in a well-ventilated area.
- Hygiene Precautions:** As for good veterinary practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

- Appearance:** Round, concave, half-scored, tan/grey film coated (2.5 mg) tablets
Round, concave, half-scored, yellow film coated (5 mg) tablets
Round, concave, half-scored, red film coated (20 mg) tablets
- Specific Gravity:** Not applicable
- Solubility in Water:** Tablets disintegrate in water
- Flash Point:** Not flammable
- pH:** Not applicable

Section 10: STABILITY AND REACTIVITY

- Stability:** When stored appropriately this product should show no significant degradation for at least 18 months from the date of manufacture.
- Hazardous Polymerisation:** Not known to occur.
- Materials to Avoid:** Not applicable.

Section 11: TOXICOLOGICAL INFORMATION

- Inhalation:** Not classified as acutely toxic by inhalation.
- Ingestion:** Not classified as acutely toxic by the oral route.
Benazepril: Oral LD50; >5000 mg/kg (rat)
- Skin:** Not classified as a skin irritant.
- Eye:** Not classified as an eye irritant.
- Chronic Effects:** Benazepril hydrochloride has been shown to be an effective and well tolerated oral agent in human patients for the chronic treatment of advanced congestive heart failure.
Ref: Mirvis, D.M. et al. Am. J. Med Sci. 1990; 300 (6): 354 – 60.
- Reproductive Toxicity:** At doses of 50 – 500 mg / kg / day, benazepril had no effect on the reproductive performance of male and female rats.
- Mutagenicity:** Not considered to be mutagenic, based on the results of animal studies.
- Carcinogenicity:** Not considered to be carcinogenic, based on the results of animal studies.

Section 12: ECOLOGICAL INFORMATION

- Ecotoxicity:** Not known to be ecotoxic.

Section 13: DISPOSAL INFORMATION

- Product Disposal:** Dispose of product only by using according to label or by approved waste collection.
- Container Disposal:** Wrap with paper and place in garbage. For bulk product containers, refer to the relevant Waste Management Authority.

Section 14: TRANSPORT INFORMATION

- Dangerous Goods Classification:** Not classed as a Dangerous Good for transport purposes by road, sea or air.

Section 15: REGULATORY INFORMATION

APVMA Registration Nos: 61589 (VetACE 2.5 mg); 61920 (VetACE 5 mg); 61583 (VetACE 20 mg).

Section 16: OTHER INFORMATION

This information is based on data believed by Jurox Pty Limited to be accurate at the time of writing but is subject to change without notice. It is given in good faith, but no warranty expressed or implied is made as to its accuracy, completeness otherwise and no assumption of liability from howsoever arising is made by Jurox Pty Limited by reason of the provision of this information. Every person dealing with the materials referred to herein does so at his/her own risk absolutely and must make independent determinations of suitability and completeness of information from all sources to ensure their proper use.